Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
People treated with direct-acting antivirals had a lower risk for liver failure and liver cancer as well as much lower mortality.
Greater political will and financial support for national programs are needed to eliminate viral hepatitis.
The three-drug combination cured most people who had experienced previous treatment failure.
ReLink programs treated 19% of people who were brought back into HCV care after being lost to follow-up.
More than 40% of the 2.4 million Americans with hepatitis C don’t know they’re infected.
Current guidelines recommend antiviral treatment regardless of alcohol use.
Two thirds of people who currently use drugs completed treatment, and most of those were cured.
People who achieved SVR two or more years ago were less likely to develop hepatocellular carcinoma than those cured more recently.
Study findings suggest HCV-RNA-positive kidneys are not inferior in the direct-acting antiviral era.
Patients allegedly failed to meet health care standards for those incarcerated with hepatitis C.
People with hepatocellular carcinoma had improved survival after the advent of direct-acting antiviral therapy.
However, people with liver cirrhosis remain at risk and should continue screening even after being cured.
The short treatment could make transplantation of organs from donors with HCV more safe, effective and economical.
People with both HIV and hepatitis C are at greater risk for myocardial infarction as they age, and traditional risk factors also matter.
Mavyret was associated with the most improvement in post-traumatic stress disorder symptoms.
Cure rate was three times as high for people who received treatment through a syringe service program.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.